It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
King Charles III has only been Britain’s reigning monarch for 18 months, yet his funeral plans are already set amid his battle with pancreatic cancer. Named “Operation Menai Bridge,” the monarch’s funeral processions will look similar to Queen Elizabeth II’s ceremonies, dubbed “Operation London Bridge.” As his cancer progresses, royal insiders tell In Touch that Charles’ final resting plans are of timely prioritization.
“It’s a fairly common thing to do among the British royalty, but in Charles’ case expediency is necessary,” says the source, who notes that “some courtiers believe Charles’ cancer is worse than they’re making it out to be.”
“Operation Menai Bridge” is set to include familiar protocols. When the monarch dies, Charles’ body will be moved from the throne room at Buckingham Palace to Westminster Hall. He will lie in state, and his official funeral will take place nine days later. He will likely be buried in the royal vault at Windsor Castle.
“It will have all the pomp and circumstance befitting a British monarch,” adds the source.
The update comes shortly after a separate high ranking royal insider told In Touch that Charles is not only battling pancreatic cancer – a timely update given that he did not share what kind of cancer he was diagnosed with – but has a mere two years to live.
LONDON (AP) — As King Charles III receives treatment for cancer, he remains Britain's monarch and head of state. The king's older son, Prince William, is next in line for the throne. The crown does not pass from reigning monarchs to their spouses, so Queen Camilla is not in the line of succession. Feb 7, 2024
originally posted by: Freeborn
Much ado about nothing.
originally posted by: Oldcarpy2
a reply to: nerbot
"Sheeple"?
Jab?
M'kay.....
A revolutionary new cancer treatment known as mRNA therapy has been administered to patients at Hammersmith hospital in west London. The trial has been set up to evaluate the therapy’s safety and effectiveness in treating melanoma, lung cancer and other solid tumours.
A number of cancer vaccines have recently entered clinical trials across the globe. These fall into two categories: personalised cancer immunotherapies, which rely on extracting a patient’s own genetic material from their tumours; and therapeutic cancer immunotherapies, such as the mRNA therapy newly launched in London, which are “ready made” and tailored to a particular type of cancer.